Repository logo
 

Convergence of cMyc and β-catenin on Tcf7l1 enables endoderm specification.

Published version
Peer-reviewed

Repository DOI


Type

Article

Change log

Authors

Morrison, Gillian 
Scognamiglio, Roberta 
Trumpp, Andreas 

Abstract

The molecular machinery that directs formation of definitive endoderm from pluripotent stem cells is not well understood. Wnt/β-catenin and Nodal signalling have been implicated, but the requirements for lineage specification remain incompletely defined. Here, we demonstrate a potent effect of inhibiting glycogen synthase kinase 3 (GSK3) on definitive endoderm production. We find that downstream of GSK3 inhibition, elevated cMyc and β-catenin act in parallel to reduce transcription and DNA binding, respectively, of the transcriptional repressor Tcf7l1. Tcf7l1 represses FoxA2, a pioneer factor for endoderm specification. Deletion of Tcf7l1 is sufficient to allow upregulation of FoxA2 in the presence of Activin. In wild-type cells, cMyc contributes by reducing Tcf7l1 mRNA, while β-catenin acts on Tcf7l1 protein. GSK3 inhibition is further required for consolidation of endodermal fate via upregulation of Sox17, highlighting sequential roles for Wnt signalling. The identification of a cMyc/β-catenin-Tcf7l1-FoxA2 axis reveals a de-repression mechanism underlying endoderm induction that may be recapitulated in other developmental and patho-logical contexts.

Description

Keywords

FoxA2, Myc, Tcf7l1, embryonic stem cells, endoderm, Activins, Animals, Cell Differentiation, Cells, Cultured, Embryonic Stem Cells, Endoderm, Gene Expression Regulation, Glycogen Synthase Kinase 3, Hepatocyte Nuclear Factor 3-beta, Mice, Proto-Oncogene Proteins c-myc, Signal Transduction, Transcription Factor 7-Like 1 Protein, beta Catenin

Journal Title

EMBO J

Conference Name

Journal ISSN

0261-4189
1460-2075

Volume Title

35

Publisher

Springer Science and Business Media LLC
Sponsorship
Medical Research Council (G1001028)
Medical Research Council (MC_PC_12009)
MRC (G1100526)
European Commission (241883)
Wellcome Trust (097922/Z/11/B)
This study was funded by the Juvenile Diabetes Research Foundation International, the European Commission FP7 project BetaCellTherapy (agreement No. 241883), a core support grant from the Wellcome Trust and MRC to the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute, and a University of Edinburgh Chancellor’s Fellowship awarded to GM. GM was a JDRF advanced postdoctoral fellow. AS is a Medical Research Council Professor.